Woodford Debacle Is A Test Of UK Biotech’s Resilience
Investor's Downfall Is Unwelcome Distraction
As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.
You may also be interested in...
The chairman of Sofinnova Partners told Scrip his newly launched biotech start-up fund aims to profit from Europe’s top science, relatively realistic asset prices, and geopolitical position between the US and China.
After ADC Therapeutics
PPF has bought a big stake in the UK-based T-cell specialist, one of many firms backed by investor Neil Woodford which have suffered stock slides in the past few months.